1. McAlister FA, Stewart S, Ferrua S, McMurray J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission. A systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810–819. [PubMed] [Google Scholar] 2. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute heart failure 2012. Eur Heart J. 2012;33:1787–1847. [PubMed] [Google Scholar] 3. Mebazaa AM, Yilmaz B, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–558. [PubMed] [Google Scholar] 4. Riley JP, Ggabe JPN, Cowie MR. Does telemonitoring in heart failure empower patients for self-care? A qualitative study. J Clin N. 2013;22:2444–2455. [PubMed] [Google Scholar] 5. Cleland J, Dargie H, Hardman S, et al. National Heart Failure Audit: April 2012–March 2013. London: National Institute for Cardiovascular Outcomes Research; Available at: www.ucl.ac.uk/nicor/audits/heartfailure/documents/annualreports/hfannual12–13.pdf . (accessed 10th July 2015.) [Google Scholar] 6. Nicolle LE. Catheter associated urinary tract infections. Antimicrob Resist Infect Control. 2014;3:23. [PMC free article] [PubMed] [Google Scholar] 7. Gould CV, Umscheid CA, Agarwal RK, et al. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31:319–326. [PubMed] [Google Scholar] 8. Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect. 2014;86:S1–S70. (Suppl 1) [PMC free article] [PubMed] [Google Scholar] 9. Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acute illness severity in the NHS. Report of a working party. London: RCP 2012. 10. Smith GB, Prytherch DR, Meredith P, et al. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013;84:465–470. [PubMed] [Google Scholar] 11. Aiken LH, Sloane DM, Bruynell L, et al. Nurse staffing and education and hospital mortality in nine European countries: a retrospective observational study. Lancet. 2014;383:1824–1830. [PMC free article] [PubMed] [Google Scholar] 12. Cowie MR, Bell D, Butler J, et al. (2013) Acute heart failure–a call to action. Br J Cardiol. 2013;20:S1–S11. (Suppl 2) [Google Scholar] 13. Seferovic PM, Stoerk S, Filippatos G, et al. Committee of National Heart Failure Societies or Working Groups of the Heart Failure Association of the European Society of Cardiology. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail. 2013;15:947. [PubMed] [Google Scholar] 14. Ulin K, Olsson L, Wolf A, Ekman I. Person-centred care – an approach that improves the discharge process. Eur J Cardiovasc Nurs. 2015;17:1–8. [Google Scholar] 15. Lainscak M, Cleland JG, Lenzen MJ, et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Eur J Heart Fail. 2007;9:1095–1103. [PubMed] [Google Scholar] 16. Ekman I, Andreson G, Boman K, et al. Adherence and perceptions of medication in patients with chronic heart failure in patients during a five-year randomised controlled trial. Patient Educ Couns. 2006;61:348–353. [PubMed] [Google Scholar] 17. White M, Garbez R, Carroll M, et al. Is “teach-back” associated with knowledge retention and hospital readmission in hospitalized heart failure patients? J Cardiovasc Nurs. 2013;28:137–146. [PubMed] [Google Scholar] 18. Mehta PA, Dubrey SW, McIntyre HF, et al. Heart. 2009;2009;95:1851–1856. Improving survival in the six months after diagnosis of heart failure in the past decade: population-based data from the UK. [PubMed] [Google Scholar] 19. Bränström M, Boman K. Effect of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomised controlled study. Eur J Heart Fail. 2014;16:1142–1151. [PubMed] [Google Scholar] 20. Jorgenson A, Sidebottom AC, Richards H, Kirven J. A Description of Inpatient Palliative Care Actions for Patients with Acute Heart Failure. Am J Hosp Palliat Care. 2015. 2015. epub ahead of print. [PubMed] Page 2Key Roles for the Nurses in Acute Heart Failure Management
Patients with heart failure present with a variety of symptoms, most of which are non-specific. The common symptoms of congestive heart failure include fatigue, dyspnoea, swollen ankles, and exercise intolerance, or symptoms that relate to the underlying cause. The accuracy of diagnosis by presenting clinical features alone, however, is often inadequate, particularly in women and elderly or obese patients.
DyspnoeaExertional breathlessness is a frequent presenting symptom in heart failure, although it is a common symptom in the general population, particularly in patients with pulmonary disease. Dyspnoea is therefore moderately sensitive, but poorly specific, for the presence of heart failure. Orthopnoea is a more specific symptom, although it has a low sensitivity and therefore has little predictive value. Paroxysmal nocturnal dyspnoea results from increased left ventricular filling pressures (due to nocturnal fluid redistribution and enhanced renal reabsorption) and therefore has a greater sensitivity and predictive value. Nocturnal ischaemic chest pain may also be a manifestation of heart failure, so left ventricular systolic dysfunction should be excluded in patients with recurrent nocturnal angina.
Fatigue and lethargyFatigue and lethargy in chronic heart failure are, in part, related to abnormalities in skeletal muscle, with premature muscle lactate release, impaired muscle blood flow, deficient endothelial function, and abnormalities in skeletal muscle structure and function. Reduced cerebral blood flow, when accompanied by abnormal sleep patterns, may occasionally lead to somnolence and confusion in severe chronic heart failure.
OedemaSwelling of ankles and feet is another common presenting feature, although there are numerous non-cardiac causes of this symptom. Right heart failure may manifest as oedema, right hypochondrial pain (liver distension), abdominal swelling (ascites), loss of appetite, and, rarely, malabsorption (bowel oedema). An increase in weight may be associated with fluid retention, although cardiac cachexia and weight loss are important markers of disease severity in some patients. Physical examination has serious limitations as many patients, particularly those with less severe heart failure, have few abnormal signs. In addition, some physical signs are difficult to interpret and, if present, may occasionally be related to causes other than heart failure. Oedema and a tachycardia, for example, are too insensitive to have any useful predictive value, and although pulmonary crepitations may have a high diagnostic specificity they have a low sensitivity and predictive value. Indeed, the commonest cause of lower limb oedema in elderly people is immobility, and pulmonary crepitations may reflect poor ventilation with infection, or pulmonary fibrosis, rather than heart failure. Jugular venous distension has a high specificity in diagnosing heart failure in patients who are known to have cardiac disease, although some patients, even with documented heart failure, do not have an elevated venous pressure. The presence of a displaced apex beat in a patient with a history of myocardial infarction has a high positive predictive value. A third heart sound has a relatively high specificity, although its universal value is limited by a high interobserver variability, with interobserver agreement of less than 50% in non-specialists. In patients with pre-existing chronic heart failure, other clinical features may be evident that point towards precipitating causes of acute heart failure or deteriorating heart failure. Common factors that may be obvious on clinical assessment and are associated with relapses in congestive heart failure include infections, arrhythmias, continued or recurrent myocardial ischaemia, and anaemia. Several epidemiological studies, including the Framingham heart study, have used clinical scoring systems to define heart failure, although the use of these systems is not recommended for routine clinical practice.
In a patient with appropriate symptoms and a number of physical signs, including a displaced apex beat, elevated venous pressure, oedema, and a third heart sound, the clinical diagnosis of heart failure may be made with some confidence. However, the clinical suspicion of heart failure should also be confirmed with objective investigations and the demonstration of cardiac dysfunction at rest. It is important to note that, in some patients, exercise-induced myocardial ischaemia may lead to a rise in ventricular filling pressures and a fall in cardiac output, leading to symptoms of heart failure during exertion. Symptoms and exercise capacity are used to classify the severity of heart failure and monitor the response to treatment. The classification of the New York Heart Association (NYHA) is used widely, although outcome in heart failure is best determined not only by symptoms (NYHA class) but also by echocardiographic criteria. As the disease is progressive, the importance of early treatment, in an attempt to prevent progression to more severe disease, cannot be overemphasised.
Atrial fibrillationAtrial fibrillation is present in about a third (range 10-50%) of patients with chronic heart failure and may represent either a cause or a consequence of heart failure. The onset of atrial fibrillation with a rapid ventricular response may precipitate overt heart failure, particularly in patients with pre-existing ventricular dysfunction. Predisposing causes should be considered, including mitral valve disease, thyrotoxicosis, and sinus node disease. Importantly, sinus node disease may be associated with bradycardias, which might be exacerbated by antiarrhythmic treatment. No limitation in physical activity despite presence of heart disease. This can be suspected only if there is a history of heart disease which is confirmed by investigations—for example, echocardiography Slight limitation in physical activity. More strenuous activity causes shortness of breath—for example, walking on steep inclines and several flights of steps. Patients in this group can continue to have an almost normal lifestyle and employment More marked limitation of activity which interferes with work. Walking on the flat produces symptoms Unable to carry out any physical activity without symptoms. Patients are breathless at rest and mostly housebound Atrial fibrillation that occurs with severe left ventricular dysfunction following myocardial infarction is associated with a poor prognosis. In addition, patients with heart failure and atrial fibrillation are at particularly high risk of stroke and other thromboembolic complications. Ventricular arrhythmiasMalignant ventricular arrhythmias are common in end stage heart failure. For example, sustained monomorphic ventricular tachycardia occurs in up to 10% of patients with advanced heart failure who are referred for cardiac transplantation. In patients with ischaemic heart disease these arrhythmias often have re-entrant mechanisms in scarred myocardial tissue. An episode of sustained ventricular tachycardia indicates a high risk for recurrent ventricular arrhythmias and sudden cardiac death.
Sustained polymorphic ventricular tachycardia and torsades de pointes are more likely to occur in the presence of precipitating or aggravating factors, including electrolyte disturbance (for example, hypokalaemia or hyperkalaemia, hypomagnesaemia), prolonged QT interval, digoxin toxicity, drugs causing electrical instability (for example, antiarrhythmic drugs, antidepressants), and continued or recurrent myocardial ischaemia. β Blockers are useful for treating arrhythmias, and these agents (for example, bisoprolol, metoprolol, carvedilol) are likely to be increasingly used as a treatment option in patients with heart failure. Congestive heart failure predisposes to stroke and thromboembolism, with an overall estimated annual incidence of approximately 2%. Factors contributing to the increased thromboembolic risk in patients with heart failure include low cardiac output (with relative stasis of blood in dilated cardiac chambers), regional wall motion abnormalities (including formation of a left ventricular aneurysm), and associated atrial fibrillation. Although the prevalence of atrial fibrillation in some of the earlier observational studies was between 12% and 36%—which may have accounted for some of the thromboembolic events—patients with chronic heart failure who remain in sinus rhythm are also at an increased risk of stroke and venous thromboembolism. Patients with heart failure and chronic venous insufficiency may also be immobile, and this contributes to their increased risk of thrombosis, including deep venous thrombosis and pulmonary embolism.
Recent observational data from the studies of left ventricular dysfunction (SOLVD) and vasodilator heart failure trials (V-HeFT) indicate that mild to moderate heart failure is associated with an annual risk of stroke of about 1.5% (compared with a risk of less than 0.5% in those without heart failure), rising to 4% in patients with severe heart failure. In addition, the survival and ventricular enlargement (SAVE) study recently reported an inverse relation between risk of stroke and left ventricular ejection fraction, with an 18% increase in risk for every 5% reduction in left ventricular ejection fraction; this clearly relates thromboembolism to severe cardiac impairment and the severity of heart failure. As thromboembolic risk seems to be related to left atrial and left ventricular dilatation, echocardiography may have some role in the risk stratification of thromboembolism in patients with chronic heart failure. Most long term (more than 10 years of follow up) longitudinal studies of heart failure, including the Framingham heart study (1971), were performed before the widespread use of angiotensin converting enzyme inhibitors. In the Framingham study the overall survival at eight years for all NYHA classes was 30%, compared with a one year mortality in classes III and IV of 34% and a one year mortality in class IV of over 60%. The prognosis in patients whose left ventricular dysfunction is asymptomatic is better than that in those whose left ventricular dysfunction is symptomatic. The prognosis in patients with congestive heart failure is dependent on severity, age, and sex, with a poorer prognosis in male patients. In addition, numerous prognostic indices are associated with an adverse prognosis, including NYHA class, left ventricular ejection fraction, and neurohormonal status. Morbidity and mortality for all grades of symptomatic chronic heart failure are high, with a 20-30% one year mortality in mild to moderate heart failure and a greater than 50% one year mortality in severe heart failure. These prognostic data refer to patients with systolic heart failure, as the natural course of diastolic dysfunction is less well defined
Survival can be prolonged in chronic heart failure that results from systolic dysfunction if angiotensin converting enzyme inhibitors are given. Longitudinal data from the Framingham study and the Mayo Clinic suggest, however, that there is still only a limited improvement in the one year survival rate of patients with newly diagnosed symptomatic chronic heart failure, which remains at 60-70%. In these studies only a minority of patients with congestive heart failure were appropriately treated, with less than 25% of them receiving angiotensin converting enzyme inhibitors, and even among treated patients the dose used was much lower than doses used in the clinical trials.
EF ejection fraction. SOLVD-P, SOLVD-T=studies of left ventricular dysfunction prevention arm (P) and treatment arm (T). H-ISDN=hydralazine and isosorbide dinitrate. *Treatment with H-ISDN. Treatment with angiotensin converting enzyme inhibitors prevents or delays the onset of symptomatic heart failure in patients with asymptomatic, or minimally symptomatic, left ventricular systolic dysfunction. The increase in mortality with the development of symptoms suggests that the optimal time for intervention with these agents is well before the onset of substantial left ventricular dysfunction, even in the absence of overt clinical symptoms of heart failure. This benefit has been confirmed in several large, well conducted, postmyocardial infarction studies.
The mode of death in heart failure has been extensively investigated, and progressive heart failure and sudden death seem to occur with equal frequency. Some outstanding questions still remain, however. Although arrhythmias are common in patients with heart failure and are indicators of disease severity, they are not powerful independent predictors of prognosis. Sudden death may be related to ventricular arrhythmias, although asystole is a common terminal event in severe heart failure. It has not been firmly established whether these arrhythmias are primary arrhythmias or whether some are secondary to acute coronary ischaemia or indicate in situ coronary thrombosis. The cause of death is often uncertain, especially as the patient may die of a cardiac arrest outside hospital or while asleep. The table on the sensitivity, specificity, and predictive value of symptoms, signs, and chest x ray findings is adapted with permission from Harlan et al (Ann Intern Med 1977;86:133-8). R D S Watson is consultant cardiologist in the university department of medicine and the department of cardiology, City Hospital, Birmingham. The ABC of heart failure is edited by C R Gibbs, M K Davies, and G Y H Lip. CRG is research fellow and GYHL is consultant cardiologist and reader in medicine in the university department of medicine and the department of cardiology, City Hospital, Birmingham; MKD is consultant cardiologist in the department of cardiology, Selly Oak Hospital, Birmingham. The series will be published as a book in the spring. Page 2
The .gov means it’s official.
The site is secure. |
Which signs and symptoms would the nurse expect to find when assessing a patient diagnosed with acute exacerbation of congestive heart failure?
Postagens relacionadas
direito autoral © 2024 comojogaruno Inc.
